Please login to the form below

Not currently logged in
Email:
Password:

Label change for Lilly's Livalo

The US Food and Drug Administration has said Eli Lilly & Company can update the label of cholesterol drug Livalo to remove a warning against the use of the drug together with HIV treatment lopinavir/ritonavir

The US Food and Drug Administration (FDA) has said Eli Lilly & Company can update the label of cholesterol drug Livalo (pitavastatin) to remove a warning against the use of the drug together with HIV treatment lopinavir/ritonavir.

The decision follows a study investigating the effects on patients when co-administered both treatments.

Data from the study demonstrated that there was no significant impact on the blood levels of participants, with minimal interaction between the two drugs.

"Livalo showed minimal drug-drug interactions with a common antiretroviral therapy HIV patients need to fight the disease," said Dr Judith Aberg, director of Virology, Bellevue Hospital Center and director, Division of Infectious Diseases and Immunology, NYU School of Medicine. "For a patient population that is taking multiple medications, this is exciting news."

Drugs to lower cholesterol, such as Livalo, are often prescribed to patients with HIV, with elevated cholesterol a complication associated with both the virus itself and antiretroviral therapies.

18th July 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics